Mizuho on Spyre (SYRE): 'We see these results as an extremely favorable outcome'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'
April 13, 2026 8:21 AM EDTLeerink Partners analyst Thomas J. Smith reiterated an Outperform rating on Spyre (NASDAQ: SYRE).
The analyst comments "SYRE (OP) announced positive topline results from the open-label SPY001 (anti-47) monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC). Importantly, SPY001 demonstrated class-leading efficacy on the study's primary and key secondary endpoints, showing an impressive -9.2pt reduction from baseline on the primary RHI endpoint and a 40% clinical remission rate at week 12 - both data points suggesting differentiated efficacy relative to TAK's (NR)... More
